Fabian Gerlinghaus, Cellares CEO and president Omar Kurdi at the company's facility in South San Francisco

Ex­clu­sive: Cel­lares ex­pands deal with Bris­tol My­ers on CAR-T as­set, eyes man­u­fac­tur­ing ex­pan­sion

Cel­lares has ex­pand­ed its part­ner­ship deal with Bris­tol My­ers Squibb to as­sist the Big Phar­ma in de­vel­op­ing an­oth­er un­named CAR-T cell ther­a­py via its cell ther­a­py man­u­fac­tur­ing plat­form, Cell Shut­tle.

The South San Fran­cis­co com­pa­ny al­so has its eyes on long-term ex­pan­sion, which in­cludes new col­lab­o­ra­tions and new builds in US, Eu­rope and Asia, CEO Fabi­an Ger­ling­haus said. There’s been an “avalanche of in­ter­est” from phar­ma com­pa­nies look­ing to part­ner, Ger­ling­haus told End­points News in an in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.